ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone payments. The drug candidate entered Phase 1 clinical trials in December. It targets an antigen called delta-like ligand 3 (DLL3), which is overexpressed in certain cancers, including small-cell lung cancer and other neuroendocrine tumors. Innovent says it may be useful in tumors that are resistant to chemotherapy.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X